Announcements Trials
Browse Landscape

Phase

Phase 4 6Phase NA 5Phase 2 5Phase 1 4Phase 3 2Phase 1/2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER_GOV 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Classical hematology 2Plasma cell 1Gastrointestinal 1Breast 1

Conditions

Lymphoma, Non-Hodgkin 1Hodgkin Disease 1

Interventions

Rituximab 238Cyclophosphamide 192Vincristine 164Doxorubicin 150Prednisone 126Methotrexate 80Cytarabine 79Etoposide 78Dexamethasone 72Radiotherapy 60Bendamustine Hydrochloride 58Mercaptopurine 46Lenalidomide 42pegaspargase 41Prednisolone 38Filgrastim 38ibrutinib 37fludarabine 36Bleomycin 36Daunorubicin 35obinutuzumab 34Asparaginase 33Leucovorin 29venetoclax 28Granulocyte Colony-Stimulating Factor 28Chlorambucil 27Calcium Dobesilate 27Gemcitabine 26Vinblastine 25Thioguanine 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × pegylated granulocyte colony-stimulating factor × Lymphoid × Clear all
NCT03907488 2026-06-01

Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma

National Cancer Institute (NCI)

Phase 3 Active not recruiting
994 enrolled 11 charts 1 FDA
Lymphoid

Hodgkin Disease

NCT06520163 2025-12-04

Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma

The Affiliated People's Hospital of Ningbo University

Phase 3 Recruiting
99 enrolled
Lymphoid

Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡